A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy
A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.
Inclusion Criteria:
Exclusion Criteria:
Anhui Province, China
Cuangdong Province, China
Guangdong Province, China
Guangdong Province, China
Henan Province, China
Henan Province, China
Jiangsu Province, China
Jiangsu Province, China
Jiangsu Province, China
Jiangsu Province, China
Jiangsu Province, China
Jiangxi Province, China
Jilin Province, China
Liaoning Province, China
Shanxi Province, China
Zhejiang Province, China
Zhengjiang Province, China
Kitaadachi-gun, Saitama, Japan
Sunto-gun, Shizuoka, Japan
Bunkyo-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Koto-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Jeollabuk-do, South Korea